149 related articles for article (PubMed ID: 38311012)
1. Tumor-associated macrophages in non-small-cell lung cancer: From treatment resistance mechanisms to therapeutic targets.
Huang Z; Xiao Z; Yu L; Liu J; Yang Y; Ouyang W
Crit Rev Oncol Hematol; 2024 Apr; 196():104284. PubMed ID: 38311012
[TBL] [Abstract][Full Text] [Related]
2. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
3. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective.
Xiao Y; Zhang L; Zhu J; Zhang Y; Yang R; Yan J; Huang R; Zheng C; Xiao W; Huang C; Wang Y
Biomed Pharmacother; 2021 Nov; 143():112105. PubMed ID: 34560533
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects.
Cheng D; Ge K; Yao X; Wang B; Chen R; Zhao W; Fang C; Ji M
Front Immunol; 2023; 14():1209947. PubMed ID: 37649478
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
[TBL] [Abstract][Full Text] [Related]
8. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of M2 tumor-associated macrophages in non-small-cell lung cancer.
Li Z; Wang YJ; Zhou J; Umakoshi M; Goto A
Histol Histopathol; 2022 Dec; 37(12):1167-1175. PubMed ID: 35638244
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy.
Liu L; Chen G; Gong S; Huang R; Fan C
Front Immunol; 2023; 14():1274547. PubMed ID: 38022518
[TBL] [Abstract][Full Text] [Related]
13. LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1/SOCS1 and STAT1/CIITA pathways to promote the progression of non-small cell lung cancer.
Yin C; Li J; Li S; Yang X; Lu Y; Wang C; Liu B
Cell Signal; 2024 Mar; 115():111031. PubMed ID: 38168631
[TBL] [Abstract][Full Text] [Related]
14. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
Shih CT; Shiau CW; Chen YL; Chen LJ; Chao TI; Wang CY; Huang CY; Hung MH; Chen KF
Cancer Lett; 2021 Feb; 498():142-151. PubMed ID: 33232786
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
Front Immunol; 2021; 12():756722. PubMed ID: 34804043
[TBL] [Abstract][Full Text] [Related]
16. 13-Methyl-palmatrubine shows an anti-tumor role in non-small cell lung cancer via shifting M2 to M1 polarization of tumor macrophages.
Wu Z; Zhou J; Chen F; Yu J; Li H; Li Q; Li W
Int Immunopharmacol; 2022 Mar; 104():108468. PubMed ID: 35066343
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Integrative Analysis Reveals the Association of
Arora S; Singh P; Ahmad S; Ahmad T; Dohare R; Almatroodi SA; Alrumaihi F; Rahmani AH; Syed MA
Cells; 2021 Aug; 10(8):. PubMed ID: 34440860
[TBL] [Abstract][Full Text] [Related]
18. The role of exosomal miR-181b in the crosstalk between NSCLC cells and tumor-associated macrophages.
Ma J; Chen S; Liu Y; Han H; Gong M; Song Y
Genes Genomics; 2022 Oct; 44(10):1243-1258. PubMed ID: 35150402
[TBL] [Abstract][Full Text] [Related]
19. Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms.
Zhao W; Wang H; Zhang X; Zhang L; Pu W; Ma Y; Chen W
BMC Pulm Med; 2024 Jan; 24(1):46. PubMed ID: 38254043
[TBL] [Abstract][Full Text] [Related]
20. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.
Zhao Y; Guo S; Deng J; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Wen Q; Li J; Xiao Z
Int J Biol Sci; 2022; 18(9):3845-3858. PubMed ID: 35813484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
